Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment.

Dowell, James A; Marbury, Thomas C; Smith, William B; Henkel, Tim

Dowell, James A; Marbury, Thomas C; Smith, William B; Henkel, Tim.

Affiliation

Dowell JA; Pharmacology Development Services, LLC, Collegeville, Pennsylvania, USA.
Marbury TC; Orlando Clinical Research Center, Orlando, Florida, USA.
Smith WB; Alliance for Multispecialty Research, University of Tennessee Medical Center, Knoxville, Tennessee, USA.
Henkel T; Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.

Antimicrob Agents Chemother ; 66(9): e0025322, 2022 09 20.

Article in En | MEDLINE | ID: mdl-35920662

Subject(s)

Renal Insufficiency; beta-Lactamase Inhibitors; Anti-Bacterial Agents/adverse effects; Anti-Bacterial Agents/pharmacokinetics; Borinic Acids; Carboxylic Acids; Cefepime/therapeutic use; Humans; Renal Insufficiency/drug therapy; Serine; beta-Lactamase Inhibitors/pharmacology; beta-Lactamases

Key words

VNRX-5133; beta-lactamase inhibitor; cefepime; cefepime-taniborbactam; drug safety; pharmacokinetics; renal impairment; taniborbactam

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Insufficiency / Beta-Lactamase Inhibitors Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2022 Document type: Article

Fulltext

XML

PubMed Links

Search on Google